Tyrosine kinase inhibitors still play a very important role in the treatment of metastatic renal cell carcinoma despite a continuously changing scenario, in which immunotherapy and several combination-based approaches are also available. In this light, patient-reported outcomes and health-related quality of life are important factors in the selection of the best first-line treatment. This Review focuses on the existing evidence on patient-reported outcomes and health-related quality of life with several tyrosine kinase inhibitors (pazopanib, sunitinib, cabozantinib and tivozanib) used as first-line treatment for metastatic renal cell carcinoma.
Procopio G., Pignata S., Altavilla A., Attademo L., De Lisi D., Verzoni E., et al. (2019). Role and relevance of quality indicators in the selection of first-line treatment of patients with metastatic renal cell carcinoma: A position paper of the MeetURO Group. FUTURE ONCOLOGY, 15(22), 2657-2666 [10.2217/fon-2018-0857].
Role and relevance of quality indicators in the selection of first-line treatment of patients with metastatic renal cell carcinoma: A position paper of the MeetURO Group
Pignata S.;Altavilla A.;De Giorgi U.;Santini D.
2019
Abstract
Tyrosine kinase inhibitors still play a very important role in the treatment of metastatic renal cell carcinoma despite a continuously changing scenario, in which immunotherapy and several combination-based approaches are also available. In this light, patient-reported outcomes and health-related quality of life are important factors in the selection of the best first-line treatment. This Review focuses on the existing evidence on patient-reported outcomes and health-related quality of life with several tyrosine kinase inhibitors (pazopanib, sunitinib, cabozantinib and tivozanib) used as first-line treatment for metastatic renal cell carcinoma.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
